Meta-analysis: protein supplements nudge cholesterol down in overweight adults, modestly
Pooling 32 trials, researchers found milk, whey, casein, and soy protein lowered LDL and total cholesterol slightly — but the effect shrank once weaker studies were excluded.
A meta-analysis published 22 August in Nutrition Reviews pooled 32 randomized controlled trials testing whether high-quality protein supplements — milk, casein, whey, and soy — improve cholesterol and triglyceride levels in adults who are overweight or obese [s1]. The answer: LDL and total cholesterol moved down slightly. HDL and triglycerides did not move at all.
Lipid abnormalities are common in overweight and obesity, and protein supplements are already widely used for weight management and muscle preservation. Whether they carry a side benefit for cholesterol has been unclear, with individual trials too small and too inconsistent to settle the question. This analysis, led by researchers at Ahvaz Jundishapur University of Medical Sciences and Shiraz University of Medical Sciences in Iran, tried to resolve that by combining the available evidence [s1].
What the trials showed combined
The researchers searched PubMed, Scopus, and Web of Science and identified 32 eligible RCTs — 39 intervention arms in total — covering 1,357 participants, split roughly evenly between protein-supplement groups (710) and control groups (647) [s1]. Trials varied in protein type, dose, and duration, and all enrolled adults who were overweight or obese [s1].
Pooling the results, supplementation was associated with a reduction in LDL cholesterol of 3.45 mg/dL (95% CI, −5.77 to −1.13; P = .004) and a reduction in total cholesterol of 5.70 mg/dL (95% CI, −10.20 to −1.20; P = .013) [s1]. Neither triglycerides (−4.25 mg/dL; P = .182) nor HDL cholesterol (+0.33 mg/dL; P = .574) changed by a statistically meaningful amount [s1].
How big is 3.45 mg/dL, really
Context matters here. A typical statin lowers LDL by 30 to 50 percent — on the order of 50 to 100 mg/dL for someone starting in the 130–160 mg/dL range. A 3.45 mg/dL reduction from protein supplementation is a small fraction of that, more a nudge than an intervention. The total-cholesterol reduction of 5.70 mg/dL is similarly modest in absolute terms.
The authors' own sensitivity analysis is the more important finding. When trials judged to carry a high risk of bias were excluded, the LDL and total-cholesterol effects were attenuated [s1] — meaning some of the pooled benefit was likely coming from lower-quality studies, and the effect that survives closer scrutiny is smaller still. The analysis used a GRADE framework to rate the certainty of evidence, the standard approach for flagging exactly this kind of fragility, though the paper as summarized does not give a single overall certainty grade for each outcome.
What this doesn't show
This is a meta-analysis of trials that differed in protein type, dose, and duration, combined into pooled estimates — a useful way to detect a signal across a scattered literature, but one that can't say which protein type, dose, or duration works best, or for whom. It also can't establish whether these lipid changes translate into fewer heart attacks or strokes; LDL and total cholesterol are surrogate markers, not outcomes themselves. And the null results for HDL and triglycerides matter as much as the positive ones — they argue against protein supplementation as a broad lipid-management tool, even if it does something narrow to LDL and total cholesterol.
The authors concluded that supplementation "was associated with reductions in LDL-C and TC" but called for "additional trials with longer follow-up periods" before drawing firmer conclusions [s1].
What it means for readers
For someone already using a protein supplement for weight or muscle goals, this analysis suggests a modest, uncertain side benefit for cholesterol — not a reason to start one, and not a substitute for cholesterol-lowering treatment where that is medically indicated. The honest summary is that the signal is real enough to keep studying and small enough not to change practice on its own.
What to watch next
Longer, larger, and more standardized trials that isolate a single protein type and dose, and studies that follow lipid changes through to cardiovascular outcomes rather than stopping at cholesterol numbers.
This article is informational and is not medical advice.
Sources
- Effects of High-Quality Protein Supplementation on Lipid and Lipoprotein Profiles in Overweight and Obese Adults: A GRADE-Assessed Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials — Nutrition Reviews (Oxford University Press), 22 August 2026
Sources
- Effects of High-Quality Protein Supplementation on Lipid and Lipoprotein Profiles in Overweight and Obese Adults: A GRADE-Assessed Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials — Nutrition Reviews (Oxford University Press) , August 22, 2026
More on
Which muscles hold their strength through weight loss? A gene hunt
A transcriptomic sub-study of the CALERIE calorie-restriction trial links 151 genes to preserved leg strength during weight loss, independent of how much body mass was lost.
New US dietary guidelines raise protein, cap added sugar, and leave a fat problem
The 2025–2030 edition was released January 7. It is the first to name highly processed foods, and the first whose saturated-fat arithmetic does not obviously close.
Diabetes care's annual rulebook lands, and obesity medicine moves toward the centre of it
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.
The Lancet's ultra-processed food series makes a displacement argument
Three papers published on 18 November argue the harm is not one ingredient but the replacement of whole-food diets. The evidence they assemble is strongest for diet quality and weakest where causation is hardest.